Turning Insight into Innovation in Preclinical R&D
“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...
SEND 4.0 introduces one of the most significant updates to nonclinical data standards, expanding scientific coverage and modernizing core structures across the SEND ecosystem. This white paper outlines the key changes such as new domains,...
Complete, Compliant, and SEND‑Ready Submissions for Regulatory Success
SEND Implementation Guide v4.0 is the biggest change I’ve seen to the standard in the 15 years I’ve been involved. Here’s what you need to know.
This white paper explores how SEND-aligned data management is enabling the development of virtual control groups (VCGs), a transformative approach with the potential to significantly reduce animal use in preclinical drug safety studies.
